Investment Rating - The investment rating for the company is upgraded to "Accumulate" [1] Core Insights - The company reported a 10.5% year-on-year increase in net profit attributable to the parent company for Q3 2025, indicating effective operational adjustments [7] - The company has experienced a significant improvement in profitability, with a notable recovery trend in profits over the last two quarters [7] - Strategic investments in Saint Pharma and international collaborations are expected to enhance long-term growth prospects [7] Financial Performance Summary - For Q1-Q3 2025, the company achieved total revenue of 3.16 billion, down 18.4% year-on-year, and a net profit of 250 million, down 30.3% year-on-year [7] - In Q3 2025, the company reported revenue of 900 million, a decrease of 15.2% year-on-year, but a net profit of 31.53 million, an increase of 55.6% year-on-year [7] - The gross profit margin for Q1-Q3 2025 was 70.7%, a decrease of 3.2 percentage points year-on-year, while the gross profit margin for Q3 2025 was 69.9%, a decrease of 2.5 percentage points year-on-year [7] - The company’s operating expenses ratio decreased by 4.9 percentage points year-on-year in Q3 2025, with the sales expense ratio reaching its lowest level in five years [7] Earnings Forecast and Valuation - The forecast for net profit attributable to the parent company has been revised down from 720 million and 860 million for 2025 and 2026 to 380 million and 520 million, respectively [7] - The new forecast for 2027 net profit is 620 million, with corresponding P/E ratios of 69, 50, and 42 for 2025, 2026, and 2027 [7]